Protara Therapeutics Book Value Per Share Growth & History (TARA)
Protara Therapeutics's book value per share was $3.67 for fiscal 2025.
View full Protara Therapeutics company overviewProtara Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.67 | -$1.10 | −23.15% |
| 2024 | 2024-12-31 | $4.77 | -$1.24 | −20.67% |
| 2023 | 2023-12-31 | $6.01 | -$3.05 | −33.65% |
| 2022 | 2022-12-31 | $9.06 | -$5.35 | −37.13% |
| 2021 | 2021-12-31 | $14.41 | -$3.36 | −18.91% |
| 2020 | 2020-12-31 | $17.77 | $18.58 | — |
| 2019 | 2019-12-31 | -$0.81 | -$10.74 | — |
| 2018 | 2018-12-31 | $9.93 | -$68.69 | −87.37% |
| 2017 | 2017-12-31 | $78.62 | -$13.99 | −15.10% |
| 2016 | 2016-12-31 | $92.61 | -$61.09 | −39.74% |
| 2015 | 2015-12-31 | $153.70 | -$46.83 | −23.36% |
| 2014 | 2014-12-31 | $200.53 | $16,959.50 | — |
| 2013 | 2013-12-31 | -$16,758.97 | -$1,728.03 | — |
| 2012 | 2012-12-31 | -$15,030.94 | — | — |
Protara Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.73 | -$1.01 | −27.06% |
| Q1 2026 | 2026-03-31 | $3.29 | -$0.82 | −19.88% |
| Q4 2025 | 2025-12-31 | $3.67 | -$1.10 | −23.15% |
| Q3 2025 | 2025-09-30 | $3.43 | -$0.54 | −13.53% |
| Q2 2025 | 2025-06-30 | $3.74 | -$4.36 | −53.78% |
| Q1 2025 | 2025-03-31 | $4.11 | -$1.00 | −19.58% |
| Q4 2024 | 2024-12-31 | $4.77 | -$1.24 | −20.67% |
| Q3 2024 | 2024-09-30 | $3.96 | -$2.81 | −41.45% |
| Q2 2024 | 2024-06-30 | $8.10 | $0.56 | +7.47% |
| Q1 2024 | 2024-03-31 | $5.11 | -$3.27 | −39.05% |
| Q4 2023 | 2023-12-31 | $6.01 | -$3.05 | −33.65% |
| Q3 2023 | 2023-09-30 | $6.77 | -$5.58 | −45.18% |
| Q2 2023 | 2023-06-30 | $7.54 | -$5.38 | −41.67% |
| Q1 2023 | 2023-03-31 | $8.38 | -$5.15 | −38.05% |
| Q4 2022 | 2022-12-31 | $9.06 | -$5.35 | −37.13% |
| Q3 2022 | 2022-09-30 | $12.35 | -$2.81 | −18.56% |
| Q2 2022 | 2022-06-30 | $12.92 | -$2.96 | −18.64% |
| Q1 2022 | 2022-03-31 | $13.53 | -$3.22 | −19.25% |
| Q4 2021 | 2021-12-31 | $14.41 | -$3.36 | −18.91% |
| Q3 2021 | 2021-09-30 | $15.17 | -$3.33 | −18.01% |
| Q2 2021 | 2021-06-30 | $15.88 | $5.71 | +56.14% |
| Q1 2021 | 2021-03-31 | $16.75 | $5.67 | +51.21% |
| Q4 2020 | 2020-12-31 | $17.77 | $18.58 | — |
| Q3 2020 | 2020-09-30 | $18.50 | $17.92 | +3078.90% |
| Q2 2020 | 2020-06-30 | $10.17 | $6.09 | +149.02% |
| Q1 2020 | 2020-03-31 | $11.08 | $4.29 | +63.11% |
| Q4 2019 | 2019-12-31 | -$0.81 | -$10.74 | — |
| Q3 2019 | 2019-09-30 | $0.58 | -$51.18 | −98.88% |
| Q2 2019 | 2019-06-30 | $4.08 | -$53.73 | −92.94% |
| Q1 2019 | 2019-03-31 | $6.79 | -$59.94 | −89.82% |
| Q4 2018 | 2018-12-31 | $9.93 | -$68.69 | −87.37% |
| Q3 2018 | 2018-09-30 | $51.76 | -$37.85 | −42.24% |
| Q2 2018 | 2018-06-30 | $57.81 | -$9.14 | −13.66% |
| Q1 2018 | 2018-03-31 | $66.74 | -$11.97 | −15.21% |
| Q4 2017 | 2017-12-31 | $78.62 | -$13.99 | −15.10% |
| Q3 2017 | 2017-09-30 | $89.61 | -$17.62 | −16.43% |
| Q2 2017 | 2017-06-30 | $66.96 | -$55.94 | −45.52% |
| Q1 2017 | 2017-03-31 | $78.71 | -$61.23 | −43.76% |
| Q4 2016 | 2016-12-31 | $92.61 | -$61.09 | −39.74% |
| Q3 2016 | 2016-09-30 | $107.23 | -$60.33 | −36.01% |
| Q2 2016 | 2016-06-30 | $122.90 | -$56.36 | −31.44% |
| Q1 2016 | 2016-03-31 | $139.94 | -$50.45 | −26.50% |
| Q4 2015 | 2015-12-31 | $153.70 | -$46.83 | −23.36% |
| Q3 2015 | 2015-09-30 | $167.56 | $19,543.16 | — |
| Q2 2015 | 2015-06-30 | $179.26 | — | — |
| Q1 2015 | 2015-03-31 | $190.39 | — | — |
| Q4 2014 | 2014-12-31 | $200.53 | $16,959.50 | — |
| Q3 2014 | 2014-09-30 | -$19,375.60 | — | — |
| Q4 2013 | 2013-12-31 | -$16,758.97 | — | — |
Protara Therapeutics book value per share trends
Over the last five fiscal years, Protara Therapeutics's book value per share decreased from $17.77 to $3.67, a change of -$14.11. The latest reported quarter, Q2 2026, shows $2.73.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protara Therapeutics source filings ↗